Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Sanofi logo

Sanofi

Status and phase

Completed
Phase 1

Conditions

Hepatic Impairment

Treatments

Drug: SAR302503

Study type

Interventional

Funder types

Industry

Identifiers

NCT01762462
U1111-1118-5554 (Other Identifier)
POP13450

Details and patient eligibility

About

Primary Objective: To study the effect of mild and moderate hepatic impairment on the pharmacokinetics of SAR302503. Secondary Objective: To assess the tolerability of SAR302503 given as a single dose up to 300 mg in subjects with mild and moderate and hepatic impairment and in matched subjects with normal hepatic function.

Full description

Study duration=17-35 days

Enrollment

17 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria :

  • Male or female subjects, between 18 and 75 years of age, inclusive.
  • Body weight between 50.0 and 115.0 kg, inclusive if male, and between 40.0 and 100.0 kg, inclusive if female, body mass index between 18.0 and 34.9 kg/m2, inclusive.
  • Stable chronic liver disease with Child-Pugh classification score between 5 and 9 assessed by medical history, physical examination, laboratory values
  • 12-lead ECG without clinically significant abnormality
  • Laboratory parameters within the acceptable range for subjects with hepatic impairment
  • Using a double contraception method

Exclusion criteria:

  • Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Hepatocarcinoma.
  • Acute hepatitis
  • Any significant change in chronic treatment medication within 14 days before inclusion
  • Concomitant treatment with or use of drugs or herbal agents known to be at least moderate inhibitors or inducers CYP3A4 sensitive or narrow therapeutic index substrate of CYP3A4
  • Concomitant treatment gastric pH modifying agent
  • Positive result on any of the following tests: anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab).
  • Positive result on urine drug screen
  • Positive alcohol test.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

17 participants in 1 patient group

SAR302503
Experimental group
Description:
single treatment with oral dose up to 300 mg of SAR302503
Treatment:
Drug: SAR302503

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems